InvestorsHub Logo

trader53

02/14/15 4:19 PM

#836 RE: BeeDoubleU #835

HEME - Analysis - Reinstatement / Merger

Reverse Mergers - RM's
FORM 15
15-15D

Rule 15d-6

A Reverse Merger is a technique that allows
a private company to become an instant public company.
This alternative method for completing an IPO
(Initial Public Offering)
is the catalyst that makes the price of a Shell Stock
explode!

After completing a Reverse Merger,
they can explode in price and increase in value
by 10 times, 20 times, and possibly over
100 times their original share price!



Healthmed Services Ltd.

Business Status

Development Stage Company a/o Aug 19, 2010

Shell

Incorporated In: NV, USA

HEME - Healthmed Services Ltd.
http://thestockmarketwatch.com/stock/?stock=HEME

Merger Info in Profile:
http://www.otcmarkets.com/stock/HEME/profile

HEME Website to launch soon:
http://healthmservices.com/

Share Structure
Market Value1..........$677,007 a/o Feb 13, 2015
Authorized Shares 1,000,000,000 a/o May 13, 2011
Shares Outstanding..967,153,003 a/o Jun 06, 2011
Float...............612,299,014 a/o Jun 20, 2011
Par Value 0.001

Merger Info in Profile:
http://www.otcmarkets.com/stock/HEME/profile

February 12, 2015
Reinstatement


https://nvsos.gov/sosentitysearch/corpActions.aspx?lx8nvq=dASFlhlkcK58zFH%252bmt4ByQ%253d%253d&CorpName=HEALTHMED+SERVICES+LTD

https://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=dASFlhlkcK58zFH%252bmt4ByQ%253d%253d


15-15D
Rule 15d-6
Apr 5, 2011

By: /s/ Henry J. Smith
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7843836
http://www.otcmarkets.com/stock/HEME/filings

Business Description
The Company has acquired the rights from Dr. Henry J. Smith
to an improved Donor Organ Transport System (Patent Pending).
By reconditioning the donor organ such as the heart, kidney or liver and extending the period of time for transport, it will be possible to improve the success rates of transplants. Also, by having a device that can maintain the organ for an extended period in vitro, it will be possible to test drugs on isolated organs in vitro before starting clinical trials on patients. The Company has made significant progress in its research program and has a working model of a portable organ transport device. Initial research studies have been completed showing that isolated donor organs could be kept alive for an extended period of time using the organ transport system developed. It represents strong possibilities to be the foundation for an enterprise highly profitable to the Company and its shareholders.

A merger
has been filed with Diabetes Reference Services Inc.
to absorb thier proprietary technology into the Company. Its business model is to distribute diabetes test kits through retail outlets and online, enabling consumers in a totally confidential manner to predict their propensity to contract diabetes based on testing their saliva to detect certain significant proteins that may be present. Results are available online only to purchasers though confidential codes provided in their kits, without revealing any users' identities to anyone but the purchaser.

http://investorshub.advfn.com/Healthmed-Services-Ltd-HEME-18524/



http://www.stockscores.com/quickreport.asp?ticker=heme&x=0&y=0